logo
Twitter
Discord
Email
logo
Avanos Medical, Inc.

Avanos Medical, Inc.

NYSE•AVNS
CEO: Mr. Michael C. Greiner CPA
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2014-10-21
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Contact Information
5405 Windward Parkway, Suite 100 South, Alpharetta, GA, 30004, United States
844-428-2667
avanos.com
Market Cap
$521.21M
P/E (TTM)
-1.1
36.9
Dividend Yield
--
52W High
$21.12
52W Low
$9.30
52W Range
16%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$177.80M+4.34%
4-Quarter Trend

EPS

-$0.03-132.30%
4-Quarter Trend

FCF

$7.00M-65.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Total Net Sales Increased Total Net Sales reached $520.3 M for nine months, reflecting a 2.4% increase over prior period results.
Specialty Nutrition Sales Growth SNS segment sales were $317.8 M for nine months, driven by 9.1% volume growth across product lines.
Operating Cash Flow Improved Cash provided by operating activities totaled $46.5 M for nine months, slightly up from $42.8 M last year.
Completed Nexus Medical Acquisition Acquired Nexus Medical for $27.0 M cash plus contingent consideration, enhancing Specialty Nutrition Systems portfolio.

Risk Factors

Significant Goodwill Impairment Recorded $77.0 M goodwill impairment charge in Q2 2025 after market cap decline indicated fair value below carrying amount.
Nine Month Net Loss Reported Net Loss of $(71.6) M for nine months ended September 30, 2025, compared to $5.2 M income prior year.
Tariff and Trade Restriction Risks New and increased US tariffs pose material adverse effect risk due to reliance on Mexican manufacturing and global sourcing.
Healthcare Reimbursement Uncertainty Failure of healthcare programs to maintain coverage or reductions in reimbursement could negatively impact product demand and pricing.

Outlook

Restructuring Plan Expansion Plan expanded post-Q3 2025, expecting up to $10.0 M incremental severance costs running through the end of 2026.
Anticipated Restructuring Savings Anticipate annualized savings between $15.0 M and $20.0 M resulting from organizational structure alignment initiatives.
Nexus Valuation Finalization Expected Expect final purchase price allocation valuations for Nexus acquisition to be substantially complete by the end of 2025.
Sufficient Liquidity Expected Expect operating cash flow and borrowing capacity sufficient to fund working capital and capital expenditures next twelve months.

Peer Comparison

Revenue (TTM)

Varex Imaging CorporationVREX
$821.40M
-1.4%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

Gross Margin (Latest Quarter)

OrthoPediatrics Corp.KIDS
73.9%
+0.5 pp
Orthofix Medical Inc.OFIX
72.2%
+3.5 pp
Bioventus Inc.BVS
68.0%
+0.6 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
OFIX$592.41M-5.0-25.6%21.1%
CTKB$590.72M-91.6-1.7%2.9%
BFLY$563.29M-7.0-37.8%6.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.3%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $177.80M+4.3%
    |
    EPS: $-0.03-132.3%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $175.00M+1.9%
    |
    EPS: $-1.66-4334.7%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $167.50M+0.8%
    |
    EPS: $0.14-817.9%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $687.80M+2.2%
    |
    EPS: $-8.53-541.4%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $170.40M-0.5%
    |
    EPS: $0.09-218.2%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $171.70M+1.4%
    |
    EPS: $0.04-102.7%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $166.10M+4.3%
    |
    EPS: $-0.02+82.2%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $673.30M-1.6%
    |
    EPS: $-1.33-223.1%
    Miss